Bernard Denis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bernard Denis has a total of 313 co-authors. Here are the top co-authors by number of shared publications:
Philippe Perrin
ADECA Alsace, 122 rue de Logelbach, Colmar, France; CRCDC Grand Est, Site de Colmar, 122 rue de Logelbach, Colmar, France
20 shared publicationsIsabelle Gendre
ADECA Alsace, 122 rue de Logelbach, Colmar, France; CRCDC Grand Est, Site de Colmar, 122 rue de Logelbach, Colmar, France
19 shared publicationsP. Perrin
Association for Colorectal Cancer Screening in Alsace (ADECA Alsace), Colmar, France
7 shared publications- Erik André Sauleau
Pôle Santé Publique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
6 shared publications Olivier Bouché
Department of Digestive Oncology, Centre Hospitalier Universitaire , Reims , France
6 shared publicationsJacques Bottlaender
5 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 13 (1) , e002254
Evaluation of serrated lesion detection using different indicators: a single-centre, community-based, retrospective cohort study
Objective: There are inverse associations between both the adenoma detection rate (ADR) and the serrated lesion detection rate (SLDR) and the risk of postcolonoscopy colorectal cancer. We aimed to evaluate the SLDRs of community endoscopists and to define the most relevant quality indicator for this. Methods: A retrospective analysis was conducted on adults undergoing colonoscopy from January 2023 to June 2024 at a community hospital. ADR, sessile, proximal, large, clinically relevant and advanced SLDRs were assessed. Results: Overall, 1871 colonoscopies were evaluated, performed by 11 endoscopists. The overall ADR, sessile and proximal SLDR were respectively 27.0% (95% CI 24.6% to 29.8%), 7.0% (95% CI 5.5% to 8.4%) and 8.9% (95% CI 7.4% to 10.3%). A third of endoscopists had suboptimal SLDRs. The correlation between ADR and sessile SLDR was moderate and non-significant (r=0.57, p=0.07) but was excellent between sessile and proximal SLDR (r=0.93, p11 min vs 11 min was associated with a doubling of ADR and proximal SLDR compared with <9 min. In routine practice, the sessile and proximal SLDRs seem to be similar for assessing the detection of serrated lesions and should become major quality indicators for colonoscopy.
- 14 May 2026
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 13 (1) , e002254
Open AccessEvaluation of serrated lesion detection using different indicators: a single-centre, community-based, retrospective cohort study
Objective: There are inverse associations between both the adenoma detection rate (ADR) and the serrated lesion detection rate (SLDR) and the risk of postcolonoscopy colorectal cancer. We aimed to evaluate the SLDRs of community endoscopists and to define the most relevant quality indicator for this. Methods: A retrospective analysis was conducted on adults undergoing colonoscopy from January 2023 to June 2024 at a community hospital. ADR, sessile, proximal, large, clinically relevant and advanced SLDRs were assessed. Results: Overall, 1871 colonoscopies were evaluated, performed by 11 endoscopists. The overall ADR, sessile and proximal SLDR were respectively 27.0% (95% CI 24.6% to 29.8%), 7.0% (95% CI 5.5% to 8.4%) and 8.9% (95% CI 7.4% to 10.3%). A third of endoscopists had suboptimal SLDRs. The correlation between ADR and sessile SLDR was moderate and non-significant (r=0.57, p=0.07) but was excellent between sessile and proximal SLDR (r=0.93, p11 min vs 11 min was associated with a doubling of ADR and proximal SLDR compared with <9 min. In routine practice, the sessile and proximal SLDRs seem to be similar for assessing the detection of serrated lesions and should become major quality indicators for colonoscopy.
- 1 April 2026
- Published by JLE in Annales de biologie clinique
- Vol. 84 (2) , 00
Detection of faecal blood outside organised screening programmes: the vital role of medical biologists
Outside organised colorectal cancer (CRC) screening programmes, faecal occult blood testing helps general practitioners decide whether to refer symptomatic patients for a colonoscopy. In France, practices vary widely, have not been evaluated, and are based on several qualitative and quantitative faecal immunochemical tests (FITs) with very different performance characteristics that clinicians do not appreciate. In the United Kingdom, this practice is generally based on two recommended automated quantitative FITs and usually follows very specific recommendations. Quantitative FITs have been extensively evaluated and have demonstrated their superiority, both in organised CRC screening programmes and in the investigation of symptomatic patients, albeit with different decision thresholds. In a symptomatic patient, the threshold of 10 μg haemoglobin/gram of faeces (μg/g) from the English guidelines is not applicable in France. We suggest a threshold of 2 μg/g, offering a sensitivity of 94.7 % for the diagnosis of CRC, which must be confirmed by further studies in the French symptomatic population. The advantages of quantitative faecal immunochemical tests (FIT) are such that they will gradually replace qualitative FITs: self-collection, a single sample, at most two, lower cost, control of the pre-analytical phase, automation, a significant reduction in equivocal and uninterpretable results, control of the positivity threshold, information on the degree of urgency of colonoscopy, better analytical and clinical performance, and better cost-effectiveness ratio. It is urgent that the French National Authority for Health (HAS) draw up recommendations and a framework for use in symptomatic patients and update the nomenclature of medical biology procedures.
- 1 April 2026
- Published by JLE in Annales de biologie clinique
- Vol. 84 (2) , 00
Detection of faecal blood outside organised screening programmes: the vital role of medical biologists
Outside organised colorectal cancer (CRC) screening programmes, faecal occult blood testing helps general practitioners decide whether to refer symptomatic patients for a colonoscopy. In France, practices vary widely, have not been evaluated, and are based on several qualitative and quantitative faecal immunochemical tests (FITs) with very different performance characteristics that clinicians do not appreciate. In the United Kingdom, this practice is generally based on two recommended automated quantitative FITs and usually follows very specific recommendations. Quantitative FITs have been extensively evaluated and have demonstrated their superiority, both in organised CRC screening programmes and in the investigation of symptomatic patients, albeit with different decision thresholds. In a symptomatic patient, the threshold of 10 μg haemoglobin/gram of faeces (μg/g) from the English guidelines is not applicable in France. We suggest a threshold of 2 μg/g, offering a sensitivity of 94.7 % for the diagnosis of CRC, which must be confirmed by further studies in the French symptomatic population. The advantages of quantitative faecal immunochemical tests (FIT) are such that they will gradually replace qualitative FITs: self-collection, a single sample, at most two, lower cost, control of the pre-analytical phase, automation, a significant reduction in equivocal and uninterpretable results, control of the positivity threshold, information on the degree of urgency of colonoscopy, better analytical and clinical performance, and better cost-effectiveness ratio. It is urgent that the French National Authority for Health (HAS) draw up recommendations and a framework for use in symptomatic patients and update the nomenclature of medical biology procedures.
- 1 March 2026
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 33 (3) , 307-312
Colorectal cancer prevention and screening: righting the ship to avoid sinking
- 1 March 2026
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 33 (3) , 307-312
Colorectal cancer prevention and screening: righting the ship to avoid sinking
Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study
Background: Depending on the colorectal cancer (CRC) screening programme, a colonoscopy should be performed within 1–3 months after a positive faecal immunochemical test (FIT) result. However, such short timescales may be difficult to meet and seem trivial when most CRCs take years to develop. Objective: To assess the impact of time to colonoscopy on CRC outcomes. Design: This French nationwide retrospective cohort study included individuals with a positive FIT result between 2016 and 2019 and a subsequent colonoscopy performed within 24 months. The risks of CRC, advanced-stage CRC and advanced adenoma (AA) according to time interval to colonoscopy were assessed and evaluated on individual and socio-geographic characteristics. Results: Overall, 374 113 FIT-positive individuals underwent post-FIT colonoscopy (86.6% compliance rate), with 21 616 CRCs and 122 359 AAs diagnosed. Compared with the 2–3 months interval class, no increased risk of CRC, advanced-stage CRC or AA was observed after 3 months up to 24 months, with adjusted odds ratio after 12 months at 0.93 (0.95 CI 0.83 to 1.03), 1.04 (0.85 to 1.25) and 0.88 (0.82 to 0.93), respectively. Individuals with high faecal haemoglobin concentrations (f-Hb ≥200 µg/g) were respectively eight, eleven and two times more likely to have a CRC, an advanced-stage CRC or an AA as compared with the 30–40 µg/g class. Conclusion: No increased risk of CRC, advanced-stage CRC or AA was observed up to 24 months. Our findings suggest that ensuring colonoscopy compliance after a positive FIT may take precedence over rigid adherence to interval. The higher the f-Hb, the sooner the colonoscopy should be performed.
Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study
Background: Depending on the colorectal cancer (CRC) screening programme, a colonoscopy should be performed within 1–3 months after a positive faecal immunochemical test (FIT) result. However, such short timescales may be difficult to meet and seem trivial when most CRCs take years to develop. Objective: To assess the impact of time to colonoscopy on CRC outcomes. Design: This French nationwide retrospective cohort study included individuals with a positive FIT result between 2016 and 2019 and a subsequent colonoscopy performed within 24 months. The risks of CRC, advanced-stage CRC and advanced adenoma (AA) according to time interval to colonoscopy were assessed and evaluated on individual and socio-geographic characteristics. Results: Overall, 374 113 FIT-positive individuals underwent post-FIT colonoscopy (86.6% compliance rate), with 21 616 CRCs and 122 359 AAs diagnosed. Compared with the 2–3 months interval class, no increased risk of CRC, advanced-stage CRC or AA was observed after 3 months up to 24 months, with adjusted odds ratio after 12 months at 0.93 (0.95 CI 0.83 to 1.03), 1.04 (0.85 to 1.25) and 0.88 (0.82 to 0.93), respectively. Individuals with high faecal haemoglobin concentrations (f-Hb ≥200 µg/g) were respectively eight, eleven and two times more likely to have a CRC, an advanced-stage CRC or an AA as compared with the 30–40 µg/g class. Conclusion: No increased risk of CRC, advanced-stage CRC or AA was observed up to 24 months. Our findings suggest that ensuring colonoscopy compliance after a positive FIT may take precedence over rigid adherence to interval. The higher the f-Hb, the sooner the colonoscopy should be performed.
- Open Access
- 21 August 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (7) , 1289-1294
Systematic Evaluation of Helicobacter pylori Susceptibility to Antibiotics Before First‐Line Treatment: A Cohort Study
Background: European guidelines recommend that susceptibility tests be routinely performed, even before prescribing first‐line treatment of Helicobacter pylori infection. However, empirical treatments are the rule in France, and susceptibility‐guided treatments are the exception. Objective: We aimed to report our experience of systematic antibiotic susceptibility testing before first‐line treatment. Methods: Prospective registration of all esofagogastroduodenoscopies performed in a community hospital from December 2023 to December 2024. Antral and fundic biopsies were performed, at the discretion of the endoscopist, for histological examination, polymerase chain reaction (PCR) and culture without any freezing. Results: Overall, 3566 adults underwent esofagogastroduodenoscopy, 1785 (50.1%) were tested and H. pylori infection was diagnosed in 308 (17.3%) [95% confidence interval (CI): 15.5%–19.0%] individuals. The sensitivity of PCR for the diagnosis of H. pylori infection was 99.7%, significantly higher than those of histology (94.1%) and culture (95.2%) ( p < 0.01). Clarithromycin resistance was observed in 22.6% [95% CI: 17.9%–27.3%] and levofloxacin resistance in 18.6% [95% CI: 14.1%–23.2%] of cases. Among 285 patients treated, susceptibility‐guided triple therapy was prescribed in 84.9% of cases (73.3% amoxicillin‐clarithromycin, 11.6% amoxicillin‐levofloxacin) and quadruple bismuth therapy in 14.4% of cases. The eradication rates were 98.1% [95% CI: 96.0%–100%] for triple therapy amoxicillin‐clarithromycin and 100% [95% CI: 100%–100%] for amoxicillin‐levofloxacin, significantly higher than 81.3% [95% CI: 67.7%–94.8%] for quadruple bismuth therapy ( p < 0.01 and p = 0.03, respectively). Overall, of 218 (70.8%) patients evaluated by the C13 urea breath test, H. pylori was eradicated in 209 (95.9%) [95% CI: 93.2%–98.5%] patients. The PCR‐based diagnostic and therapeutic strategy was more cost‐effective than the immunohistochemistry‐based strategy. Conclusion: A PCR‐based susceptibility‐guided strategy is easy to implement in routine clinical practice. In more than 7 in 10 patients, PCR enabled the offer of a susceptibility‐guided triple therapy that was more effective and less costly than empirical quadruple bismuth therapy. Culture enabled one additional patient in 10 to be offered a susceptibility‐guided triple therapy.
- 21 August 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (7) , 1289-1294
Open AccessSystematic Evaluation of Helicobacter pylori Susceptibility to Antibiotics Before First‐Line Treatment: A Cohort Study
Background: European guidelines recommend that susceptibility tests be routinely performed, even before prescribing first‐line treatment of Helicobacter pylori infection. However, empirical treatments are the rule in France, and susceptibility‐guided treatments are the exception. Objective: We aimed to report our experience of systematic antibiotic susceptibility testing before first‐line treatment. Methods: Prospective registration of all esofagogastroduodenoscopies performed in a community hospital from December 2023 to December 2024. Antral and fundic biopsies were performed, at the discretion of the endoscopist, for histological examination, polymerase chain reaction (PCR) and culture without any freezing. Results: Overall, 3566 adults underwent esofagogastroduodenoscopy, 1785 (50.1%) were tested and H. pylori infection was diagnosed in 308 (17.3%) [95% confidence interval (CI): 15.5%–19.0%] individuals. The sensitivity of PCR for the diagnosis of H. pylori infection was 99.7%, significantly higher than those of histology (94.1%) and culture (95.2%) ( p < 0.01). Clarithromycin resistance was observed in 22.6% [95% CI: 17.9%–27.3%] and levofloxacin resistance in 18.6% [95% CI: 14.1%–23.2%] of cases. Among 285 patients treated, susceptibility‐guided triple therapy was prescribed in 84.9% of cases (73.3% amoxicillin‐clarithromycin, 11.6% amoxicillin‐levofloxacin) and quadruple bismuth therapy in 14.4% of cases. The eradication rates were 98.1% [95% CI: 96.0%–100%] for triple therapy amoxicillin‐clarithromycin and 100% [95% CI: 100%–100%] for amoxicillin‐levofloxacin, significantly higher than 81.3% [95% CI: 67.7%–94.8%] for quadruple bismuth therapy ( p < 0.01 and p = 0.03, respectively). Overall, of 218 (70.8%) patients evaluated by the C13 urea breath test, H. pylori was eradicated in 209 (95.9%) [95% CI: 93.2%–98.5%] patients. The PCR‐based diagnostic and therapeutic strategy was more cost‐effective than the immunohistochemistry‐based strategy. Conclusion: A PCR‐based susceptibility‐guided strategy is easy to implement in routine clinical practice. In more than 7 in 10 patients, PCR enabled the offer of a susceptibility‐guided triple therapy that was more effective and less costly than empirical quadruple bismuth therapy. Culture enabled one additional patient in 10 to be offered a susceptibility‐guided triple therapy.
- 1 November 2024
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 31 (9) , 901-914
Quantitative fecal immunochemical testing for the investigation of symptomatic patients: a revolution from the British Isles
- 1 November 2024
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 31 (9) , 901-914
Quantitative fecal immunochemical testing for the investigation of symptomatic patients: a revolution from the British Isles
- 1 November 2024
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 31 (9) , 915-926
Do you know your proximal serrated lesions detection rate? New major quality indicator for colonoscopy
- 1 November 2024
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 31 (9) , 915-926
Do you know your proximal serrated lesions detection rate? New major quality indicator for colonoscopy
- 19 January 2024
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 48 (2) , 102285
Post-colonoscopy colorectal cancer: A population-based cohort study of fecal occult blood test-positive colonoscopies
- 19 January 2024
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 48 (2) , 102285
Post-colonoscopy colorectal cancer: A population-based cohort study of fecal occult blood test-positive colonoscopies
- 1 November 2023
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 30 (9) , 919-930
Post-colonoscopy interval colorectal cancer: the dread of every endoscopist
- 1 November 2023
- Published by JLE in Hépato-Gastro & Oncologie Digestive
- Vol. 30 (9) , 919-930
Post-colonoscopy interval colorectal cancer: the dread of every endoscopist